By Connor Hart
Shares of Trinity Biotech climbed after the company released what it called compelling results from a study of its next-generation continuous glucose monitoring system, a device used for diabetes management that measures blood sugar levels in real time.
The stock was up 41%, to $1.07, in midday trading Tuesday. Shares are down 52% in the past 52 weeks.
The Dublin-based biotechnology company on Tuesday said the new system demonstrated better signal quality, accuracy and consistency than did previous generations in a recent trial involving 30 diabetic participants.
The new system also features a reusable applicator and a rechargeable wearable transmitter, eliminating costly disposable components and allowing the product to be made at a significantly lower cost, Trinity said.
Moving forward, the company said it expects to complete further clinical trials on the device. It remains on track to file for regulatory approval in the EU in 2025, and in the U.S. in 2026.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
January 28, 2025 11:59 ET (16:59 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.